• Hikma Pharmaceuticals narrowed its 2026 operating profit guidance to $740 million-$760 million, raising the lower end from $720 million.
• Group revenue growth guidance remained unchanged at 2%-4%.
• Branded revenue growth is now forecast at around 10%, up from 6%-8%.
• The Branded core operating margin outlook rose to close to 27% from 25%, supported by favorable product and market mix.
• Injectables core operating margin guidance remained at 27%-28%, despite supplier disruptions that resulted in around $15 million in failure-to-supply penalties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.